Verici Dx plc (LON:VRCI – Get Free Report)’s stock price traded up 14.3% on Friday . The stock traded as high as GBX 0.40 and last traded at GBX 0.40. 832,000 shares were traded during trading, a decline of 51% from the average session volume of 1,684,113 shares. The stock had previously closed at GBX 0.35.
Verici Dx Stock Performance
The company has a current ratio of 3.94, a quick ratio of 8.49 and a debt-to-equity ratio of 3.03. The firm’s fifty day moving average price is GBX 0.40 and its 200-day moving average price is GBX 0.54. The firm has a market cap of £11.95 million, a price-to-earnings ratio of -0.44 and a beta of 1.26.
About Verici Dx
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Featured Stories
- Five stocks we like better than Verici Dx
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
- Why “Big Short” Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
